Literature: Membranous nephropathy and autoantibodies

The following list represents a selection of current publications on primary membranous nephropathy as well as anti-PLA2R, anti-THSD7A and anti-NELL1 autoantibodies. The references are sorted by publication date.

1. Dähnrich C, Saschenbrecker S, Gunnarsson I, Schlumberger W, Ronco P, Debiec H. Development of a Standardized Chemiluminescence Immunoassay for the Detection of Autoantibodies Against Human M-Type Phospholipase A2 Receptor in Primary Membranous Nephropathy.Kidney Int (2019)
2. Hoxha E, Beck LH, Wiech T, Tomas NM, Probst C, Mindorf S, Meyer-Schwesinger C, Zahner G, Stahl PR, Schöpper R, Panzer U, Harendza S, Helmchen U, Salant DJ, Stahl RA. An indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain-containing 7A-specific antibodies in membranous nephropathy. J Am Soc Nephrol (2017)
3. Gupta G, Fattah H, Ayalon R, Kidd J, Gehr T, Quintana LF, Kimball P, Sadruddin S, Massey HD, Kumar D, King AL, Beck LH. Pre-transplant phospholipase A2 receptor autoantibody concentration is associated with clinically significant recurrence of membranous nephropathy post-kidney transplantation. Clin Transplant (2016)
4. Radice A, Trezzi B, Maggiore U, Pregnolato F, Stellato T, Napodano P, Rolla D, Pesce G, D'Amico M, Santoro D, Londrino F, Ravera F, Ortisi G, Sinico RA. Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN). Autoimmun Rev (2016)
5. Hoxha E, Thiele I, Zahner G, Panzer U, Harendza S, Stahl RAK. Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. J Am Soc Nephrol (2014)
6. Tomas NM, Beck LH Jr, Meyer-Schwesinger C, Seitz-Polski B, Ma H, Zahner G, Dolla G, Hoxha E, Helmchen U, Dabert-Gay AS, Debayle D, Merchant M, Klein J, Salant DJ, Stahl RA, Lambeau G. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med (2014)
7. Dähnrich C, Komorowski L, Probst C, Seitz-Polski B, Esnault V, Wetzels JF, Hofstra JM, Hoxha E, Stahl RA, Lambeau G, Stöcker W, Schlumberger W. Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy. Clin Chim Acta (2013)
8. Hofstra JM, Beck LH Jr, Beck DM, Wetzels JF, Salant DJ. Anti-phospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol (2011)
9. Hoxha E, Harendza S, Zahner G, Panzer U, Steinmetz O, Fechner K, Helmchen U, Stahl RA. An immunofluorescence test for phospholipase-A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant (2011)
10. Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ. M-Type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med (2009)

1. Caza TM, Arivett BA, Hassen SI, Al-Rabadi LF, Takayama S, Ibrahim A, Larsen CP, Borza DB. Detection and characterization of NELL1 autoantibodies in NELL1 positive membranous nephropathy. Kidney International (2025).
2. Hyodo T, Hara S, Goto S, Fujii H, Nishi S, Yoshimoto A, Itoh T. Clinicopathological characteristics of neural epidermal growth factor-like 1 protein-associated membranous glomerulonephritis. Virchows Archiv (2025).

1. Cremoni M, Teisseyre M, Thaunat O, Fernandez C, Payre C, Moutou A, Zarif H, Brglez V, Albano L, Moal V, Mourad G, Morelon E, Hurault de Ligny B, Zaoui P, Rondeau E, Ouali N, Ronco P, Moulin B, Braun-Parvez L, Durrbach A, Heng AE, Grimbert P, Ducloux D, Blancho G, Merville P, Choukroun G, Le Meur Y, Vigneau C, Mariat C, Rostaing L, Subra JF, Taupin JL, Lambeau G, Esnault V, Sicard A, Seitz-Polski B. Anti Phopholipase A2 Receptor 1 Antibodies and Membranous Nephropathy Recurrence After Kidney Transplantation. Kidney International Reports (2024).
2. Narayanasami S, Vijayakumar NA, Trivedi M, Sekar A, Sulaiman S, Nayak S, Inamdar N, Sharma S, Parthasarathy R, Kadam V, Keskar V, Bagai S, Kumar A, Reen B, Kurien AA, Sharma A, Khullar D, Hafeeq B, Krishnakumar A, Rahman KV S, NA I, Nair S, Divyaveer S, Rathi M, Singh Kohli H, Nada R, Ramachandran R. Clinical Characteristics and Outcomes of Neural Epidermal Growth Factor-like 1 Protein-Associated Membranous Nephropathy. Kidney International Reports (2024).

1. Ragy O, Rautemaa V, Smith A, Brenchley P, Kanigicherla D, Hamilton P. Can use of the serum anti-PLA2R antibody negate the need for a renal biopsy in primary membranous nephropathy? PLoS ONE (2023).
2. Sethi S, Beck LH, Glassock RJ, Haas M, De Vriese AS, Caza TN, Hoxha E, Lambeau G, Tomas NM, Madden B, Debiec H, D’Agati VD, Barbour SJ, Caravaca-Fontan F, Cattran DC, Casal Moura M, D’Avila DO, Eick RG, Garovic VD, Greene EL, Herrera Hernandez LP, Jenette C, Lieske JC, Markowitz GS, Nath KA, Nasr SH, Nast CC, Pani A, Praga M, Remuzzi G, Rennke HG, Ruggenenti P, Roccatello D, Soler MJ, Specks U, Stahl RAK, Singh RD, Theis JD, Velosa JA, Wetzels JFM, Winearls CG, Yandian F, Zand L, Ronco P, Fervenza FC. Mayo Clinic Consensus Report on Membranous Nephropathy: Proposal for a Novel Classification. Mayo Clinic Proceedings (2023).
3. Sethi S. The many faces of NELL1 MN. Clinical Kidney Journal (2023).
4. Vink CH, van de Logt AE, van der Molen RG, Hofstra JM, Wetzels JFM. Antibody-Guided Therapy in Phospholipase A2 Receptor-Associated Membranous Nephropathy (2023).

1. Hoxha E, Reinhard L, Stahl RA. Membranous nephropathy: new pathogenic mechanisms and their clinical implications. Nature Reviews (2022).
2. Iwakura T, Ema C, Isobe S, Fujikura T, Ohashi N, Kato A, Yasuda H. Prevalence of neural epidermal growth factor-like-1 and exostosin 1/exostosin 2-associated membranous nephropathy: a single-center retrospective study in Japan. Nat Scientific Reports (2022).

1. Hoxha E, Stahl R, Reinhard L, Kühnl A, Schlumberger W, Dähnrich C. A new chemiluminescence immunoassay for phospholipase A2 receptor 1 autoantibodies allows early identification of autoantibody recurrence in patients with membranous nephropathy. Kidney Int Rep (2021)
2. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the managemen of glomerular diseases. Kidney Int Suppl (2021)
3. Ronco P, Beck L, Debiec H, Fervenza FC, Hou FF, Jha V, Sethi S, Tong A, Vivarelli M, Wetzels J. Membranous nephropathy. Nat Rev Dis Primers (2021)
4. Tomas NM, Huber TB, Hoxha E. Perspectives in membranous nephropathy. Cell Tissue Res (2021)

1. Burbelo PD, Joshi M, Chaturvedi A, Little DJ, Thurlow JS, Waldman M, Olson SW. Detection of PLA2R autoantibodies before the diagnosis of membranous nephropathy. J Am Soc Nephrol (2020)
2. Ronco P, Debiec H. Molecular pathogenesis of membranous nephropathy. Annu Rev Pathol (2020)
3. Trujillo H, Alonso M, Praga M. New ways of understanding membranous nephropathy. Nephron (2020)

1. Dähnrich C, Saschenbrecker S, Gunnarsson I, Schlumberger W, Ronco P, Debiec H. Development of a standardized chemiluminescence immunoassay for the detection of autoantibodies against human M-Type phospholipase A2 receptor in primary membranous nephropathy. Kidney Int Rep (2019)
2. Rodas LM, Matas-Garcia A, Barros X, Blasco M, Vinas O, Llobell A, Martin N, Quintana LF. Antiphospholipase 2 receptor antibody levelst o predict complete spontaneous remission in primary membranous nephropathy. Clin Kidney J (2019)
3. Van de Logt AE, Fresquet M, Wetzels JF, Brenchley P. The anti-PLA2R antibody in membranous nephropathy: what we know and what remains a decade after ist discovery. Kidney Int (2019)

1. Beck, LH. PLA2R and THSD7A: Disparate paths to the same disease? J Am Soc Nephrol (2017)
2. Couser, WG. Primary membranous nephropathy. Clin J Am Soc Nephrol (2017)
3. De Vriese AS, Glassock RJ, Nath KA, Sethi S, Fervenza FC. A proposal for a serology-based approach to membranous nephropathy. J Am Soc Nephrol (2017)
4. Pourcine F, Dahan K, Mihout F, Cachanado M, Brocheriou I, Debiec H, Ronco P. Prognostic value of PLA2R autoimmunity detected by measurment of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: A single-centre study over 14 years. PLoS One (2017)
5. Stahl, PR, Hoxha E, Wiech T, Schröder C, Simon R, Stahl RA. THSD7A expression in human cancer. Genes Chromosomes Cancer (2017)
6. Tomas NM, Meyer-Schwesinger C, von Spiegel H, Kotb AM, Zahner G, Hoxha E, Helmchen U, Endlich N, Koch-Nolte F, Stahl RA. A heterologous model of thrombospondin type 1 domain-containing 7a-associated membranous nephropathy. J Am Soc Nephrol (2017)

1. Francis JM, Beck LH Jr, Salant DJ. Membranous nephropathy: A journey from bench to bedside. Am J Kidney Dis (2016)
2. Larsen CP, Cossey LN, Beck LH. THSD7A staining of membranous glomerulopathy in clinical practice reveals cases with dual autoantibody positivity. Mod Pathol (2016)

1. Fresquet M, Jowitt TA, Gummadova J, Collins R, O'Cualain R, McKenzie EA, Lennon R, Brenchley PE. Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy. J Am Soc Nephrol (2015)
2. Ruggenenti P, Debiec H, Ruggiero B, Chianca A, Pellé T, Gaspari F, Suardi F, Gagliardini E, Orisio S, Benigni A, Ronco P, Remuzzi G. Anti-phospholipase A2 receptor antibody titer predicts post-Rituximab outcome of membranous nephropathy. J Am Soc Nephrol (2015)

1. Hoxha E, Harendza S, Pinnschmidt H, Panzer U, Stahl RA. M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy. Clin J Am Soc Nephrol (2014)
2. Seitz-Polski B, Payré C, Ambrosetti D, Albano L, Cassuto-Viguier E, Berguignat M, Jeribi A, Thouret MC, Bernard G, Benzaken S, Lambeau G, Esnault VLM. Predicition of membranous nephropathy recurrence after transplantation by monitoring of anti-PLA2R1 (M-type phospholipase A2 receptor) autoantibodies: a case series of 15 patients. Nephrol Dial Tranplant (2014)

1. Hofstra JM, Fervenza FC, Wetzels JFM. Treatment of idiopathic membranous nephropathy. Nat Rev Nephrol (2013)
2. Hofstra JM, Debiec H, Short CD, Pellé T, Kleta R, Mathieson PW, Ronco P, Brenchley PE, Wetzels JF. Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. Clin J Am Soc Nephrol (2012)
3. Hoxha E, Kneißler U, Stege G, Zahner G, Thiele I, Panzer U, Harendza S, Helmchen UM, Stahl RA. Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney Int (2012)
4. Ronco P, Debiec H. Pathogenesis of membranous nephropathy: recent advances and future challenges. Nat Rev Nephrol (2012)
5. Beck LH Jr, Fervenza FC, Beck DM, Bonegio RG, Malik FA, Erickson SB, Cosio FG, Cattran DC, Salant DJ. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol (2011)
6. Debiec H, Ronco P. Nephrotic syndrome: A new specific test for idiopathic membranous nephropathy. Nat Rev Nephrol (2011)
7. Debiec H, Ronco P. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N Engl J Med (2011)
8. Beck Jr LH, Salant DJ. Membranous nephropathy: recent travels and new roads ahead. Kidney Int (2010)
9. Stahl R, Hoxha E, Fechner K. PLA2R autoantibodies and recurrent membranous nephropathy after transplantation. N Engl J Med (2010)
10. El-Zoghby ZM, Grande JP, Fraile MG, Norby SM, Fervenza FC, Cosio FG. Recurrent idiopathic membranous nephropathy: early diagnosis by protocol biopsies and treatment with anti-CD20 monoclonal antibodies. Am J Transplant (2009)